Comparing Bio-Path (NASDAQ:BPTH) and Evofem Biosciences (NASDAQ:EVFM)

Valuation and Earnings

This table compares Evofem Biosciences and Bio-Path”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39 million	0.10	$52.98 million	($0.06)	-0.16
Bio-Path	N/A	N/A	-$16.08 million	($1.06)	-0.07

Evofem Biosciences has higher revenue and earnings than Bio-Path. Evofem Biosciences is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evofem Biosciences and Bio-Path’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
Bio-Path	N/A	-2,842.40%	-337.48%

Insider and Institutional Ownership

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Evofem Biosciences has a beta of -1.3, meaning that its share price is 230% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500.

Summary

Evofem Biosciences beats Bio-Path on 6 of the 10 factors compared between the two stocks.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

About Bio-Path

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.